Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04704336 · ClinicalTrials.gov registry record · NA

Integration of Hypertension Management Into HIV Care in Nigeria

A NA study of Hypertension and Human Immunodeficiency Virus, sponsored by NYU Langone Health.

Active
Registry status
NA
Development phase
830
Enrollment target
2
Study locations

NCT04704336 is a NA study of Hypertension and Human Immunodeficiency Virus that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 830 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04704336, a NA study of Hypertension and Human Immunodeficiency Virus, is active but no longer recruiting, sponsored by NYU Langone Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
830 participants
Enrollment target
2
Study locations

Study Summary

This study evaluates a tailored-practice facilitation (PF) strategy for integrating a task strengthening strategy for hypertension control (TASSH) for the care of patients living with HIV (PWH) within primary health centers (PHCs) in Lagos, Nigeria.

Interventions

  • BEHAVIORAL Task-shifting strategy for HTN control (TASSH) protocol

Study Locations (2)

Missouri

  • Saint Louis University (SLU) - St Louis

Lagos

  • Nigerian Institute of Medical Research (NIMR) - Yaba

Trial Details

FieldValue
Enrollment Target 830 participants
Start Date 2021-09-13
Est. Completion 2026-01-31
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT04704336

The ClinicalTrials.gov registry entry for NCT04704336 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (76% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Task-shifting strategy for HTN control (TASSH) protocol is the first listed.

NCT04704336 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Lagos.

Frequently Asked Questions

What is clinical trial NCT04704336 about?

NCT04704336 is a clinical study titled "Integration of Hypertension Management Into HIV Care in Nigeria". This study evaluates a tailored-practice facilitation (PF) strategy for integrating a task strengthening strategy for hypertension control (TASSH) for the care of patients living with HIV (PWH) within primary health centers (PHCs) in Lagos, Nigeria.

What is the current status of trial NCT04704336?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 830 participants. The study started on 2021-09-13. Estimated completion is 2026-01-31.

What conditions does trial NCT04704336 study?

This clinical trial studies the following conditions: Hypertension, Human Immunodeficiency Virus.

What interventions are being tested in trial NCT04704336?

The interventions under investigation include: Task-shifting strategy for HTN control (TASSH) protocol (BEHAVIORAL).

Who is sponsoring clinical trial NCT04704336?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04704336 being conducted?

This trial has 2 study locations across Missouri, Lagos. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.